EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems

Halis K Akturk iD, Tadej Battelino iD, Javier Castañeda, Arcelia Arrieta, Tim van den Heuvel iD, Ohad Cohen iD

Diabetes Technology & Therapeutics · 2024-03 · 26 (3_suppl) · 102-106

DOI: 10.1089/dia.2023.0432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 05.02.2024. Verfasst von Halis K Akturk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The concept of maintaining blood glucose levels within the 70–180 mg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70–140 mg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsDiabetes Mellitus, Type 1HumansInsulinGoalsInsulin Infusion SystemsBlood GlucoseBlood Glucose Self-Monitoring

Stichwörter der Autor:innen

Automated insulin deliveryClosed-loopGlucose controlInsulin pumpInsulin therapyMiniMed™Time in tight range

Substanzen

Hypoglycemic AgentsInsulinBlood Glucose

Autor:innen und Institutionen

  • Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.
  • University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Medtronic International Trading Sàrl, Tolochenaz, Switzerland.

ORCID-Profile: Halis K Akturk, Tadej Battelino, Tim van den Heuvel, Ohad Cohen

Zitieren

APA

Akturk, H. K., Battelino, T., Castañeda, J., Arrieta, A., van den Heuvel, T., & Cohen, O. (2024). Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics, 26(3_suppl), 102-106. https://doi.org/10.1089/dia.2023.0432

Vancouver

Akturk HK, Battelino T, Castañeda J, Arrieta A, van den Heuvel T, Cohen O. Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics. 2024;26(3_suppl):102-106. doi:10.1089/dia.2023.0432

BibTeX
@article{Akturk2024,
  author = {Akturk, Halis K and Battelino, Tadej and Castañeda, Javier and Arrieta, Arcelia and van den Heuvel, Tim and Cohen, Ohad},
  title = {Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems},
  journal = {Diabetes Technology & Therapeutics},
  year = {2024},
  volume = {26},
  number = {3_suppl},
  pages = {102--106},
  doi = {10.1089/dia.2023.0432}
}
Kostenlos starten →